Defects in the apoptotic pathway represent a critical element in the progression of neoplastic disease and may also concur to determine treatment efficacy at the cellular level. Fas (Apo-1/CD95) is a cell-surface receptor involved in cell death signaling. In this study we analyzed, by immunohistochemistry, the expression of Fas protein in a group of 68 NSCLC (non-small cell lung cancer) specimens. Statistical analyses did not show any significant relationship between Fas immunohistochemical expression and clinical parameters of lung cancer patients, except for nodal status. Our data do not support the use of Fas as a molecular prognostic role in NSCLC. On the other hand, considering the role of the Fas-pathway in chemotherapy-induced apoptosis, further studies are required to analyze the potential value of Fas expression in predicting the response of NSCLC patients to chemotherapy.

Esposito, V., Baldi, A., Liuzzi, G., Tonini, G., Vincenzi, B., Persichetti, P., et al. (2003). Analysis of Fas (Apo-1/CD95) expression in non-small cell lung cancer. ANTICANCER RESEARCH, 23, 4901-4905.

Analysis of Fas (Apo-1/CD95) expression in non-small cell lung cancer

AMBROGI, VINCENZO;MINEO, TOMMASO CLAUDIO;
2003-01-01

Abstract

Defects in the apoptotic pathway represent a critical element in the progression of neoplastic disease and may also concur to determine treatment efficacy at the cellular level. Fas (Apo-1/CD95) is a cell-surface receptor involved in cell death signaling. In this study we analyzed, by immunohistochemistry, the expression of Fas protein in a group of 68 NSCLC (non-small cell lung cancer) specimens. Statistical analyses did not show any significant relationship between Fas immunohistochemical expression and clinical parameters of lung cancer patients, except for nodal status. Our data do not support the use of Fas as a molecular prognostic role in NSCLC. On the other hand, considering the role of the Fas-pathway in chemotherapy-induced apoptosis, further studies are required to analyze the potential value of Fas expression in predicting the response of NSCLC patients to chemotherapy.
2003
Pubblicato
Rilevanza internazionale
Articolo
Nessuno
Settore MED/21 - CHIRURGIA TORACICA
English
Fas; Immunohistochemistry; Non-small cell lung cancer; Survival
Esposito, V., Baldi, A., Liuzzi, G., Tonini, G., Vincenzi, B., Persichetti, P., et al. (2003). Analysis of Fas (Apo-1/CD95) expression in non-small cell lung cancer. ANTICANCER RESEARCH, 23, 4901-4905.
Esposito, V; Baldi, A; Liuzzi, G; Tonini, G; Vincenzi, B; Persichetti, P; Santini, M; Ambrogi, V; Mineo, Tc; Montesarchio, V; Wolner, E; Baldi, F; Groeger, A
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

Questo articolo è pubblicato sotto una Licenza Licenza Creative Commons Creative Commons

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/50680
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact